A feasibility study of intravenous (IV) paclitaxel, intraperitoneal (IP) carboplatin, and IP paclitaxel in patients with epithelial ovarian carcinoma, fallopian tube carcinoma, or peritoneal carcinoma

被引：0
作者：
Nagao, S. [1 ]
Oishi, R. [1 ]
Iwasa, N. [1 ]
Shimizu, M. [1 ]
Hasegawa, K. [1 ]
Goto, T. [1 ]
Fujiwara, K. [1 ]
机构：
[1] Saitama Med Univ Int, Med Ctr, Hidaka City, Saitama, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16549
引用
收藏
页数：2
相关论文
共 50 条
[41]   A comparison of patterns of failure between patients with ovarian, fallopian tube, or primary peritoneal carcinoma undergoing intravenous versus intraperitoneal chemotherapy [J].
Neubauer, N. ;
Berry, E. ;
Catanzarite, T. ;
Schink, J. .
GYNECOLOGIC ONCOLOGY, 2012, 125 :S66-S66
[42]   Dose-dense paclitaxel and carboplatin vs. conventional paclitaxel and carboplatin as neoadjuvant chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: a retrospective study [J].
Shibutani, Takashi ;
Nagao, Shoji ;
Suzuki, Kazuhiro ;
Kaneda, Michiko ;
Yamamoto, Kasumi ;
Jimi, Tomoatsu ;
Yano, Hiroko ;
Kitai, Miho ;
Shiozaki, Takaya ;
Matsuoka, Kazuko ;
Sudo, Tamotsu ;
Yamaguchi, Satoshi .
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2020, 25 (03) :502-507
[43]   Dose-dense paclitaxel and carboplatin vs. conventional paclitaxel and carboplatin as neoadjuvant chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: a retrospective study [J].
Takashi Shibutani ;
Shoji Nagao ;
Kazuhiro Suzuki ;
Michiko Kaneda ;
Kasumi Yamamoto ;
Tomoatsu Jimi ;
Hiroko Yano ;
Miho Kitai ;
Takaya Shiozaki ;
Kazuko Matsuoka ;
Tamotsu Sudo ;
Satoshi Yamaguchi .
International Journal of Clinical Oncology, 2020, 25 :502-507
[44]   Severe hypertriglyceridemia during treatment with intraperitoneal cisplatin and paclitaxel for advanced stage fallopian tube carcinoma [J].
Lander, Megan ;
Abedin, Yasmin ;
Gabrilovich, Sofia ;
Marcus, Jenna Z. .
GYNECOLOGIC ONCOLOGY REPORTS, 2020, 32
[45]   Deliverability of Carboplatin and Weekly Paclitaxel as Adjuvant Therapy for Ovarian, Fallopian Tube and Primary Peritoneal Cancer Patients [J].
Sivakumaran, T. ;
Zaheed, M. ;
Freimund, A. ;
Beale, P. ;
Harrison, M. .
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 :72-72
[46]   Phase II study of intravenous (IV) bevacizumab and paclitaxel, and intraperitoneal (IP) cisplatin, followed by bevacizumab consolidation for advanced ovarian (O) or peritoneal (P) cancers [J].
McMeekin, D. D. ;
Lanneau, G. ;
Curiel, J. ;
Moore, K. ;
Walker, J. ;
Mannel, R. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[47]   Phase I study of carboplatin, doxorubicin and weekly paclitaxel in patients with advanced ovarian carcinoma [J].
Hess, V ;
Verrill, MW ;
Bomphray, CC ;
Vaughan, MM ;
Allen, M ;
Gore, ME .
ANNALS OF ONCOLOGY, 2003, 14 (04) :638-642
[48]   A phase II study of modified dose-dense paclitaxel and every 4-week carboplatin for the treatment of advanced-stage primary epithelial ovarian, fallopian tube, or peritoneal carcinoma [J].
Lisa N. Abaid ;
John P. Micha ;
Mark A. Rettenmaier ;
John V. Brown ;
Alberto A. Mendivil ;
Katrina L. Lopez ;
Bram H. Goldstein .
Cancer Chemotherapy and Pharmacology, 2013, 72 :101-107
[49]   Comparative phase II study of intraperitoneal (IP) versus intravenous (IV) carboplatin administration with IV paclitaxel in patients with bulky residual disease after primary debulking surgery for epithelial ovarian or primary peritoneal cancer: A Sankai Gynecology Study Group (SGSG) study [J].
Fujiwara, K. ;
Nagao, S. ;
Kigawa, J. ;
Noma, J. ;
Akamatsu, N. ;
Miyagi, Y. ;
Numa, F. ;
Okada, M. ;
Aotani, E. ;
Terakawa, N. .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[50]   A phase II study of modified dose-dense paclitaxel and every 4-week carboplatin for the treatment of advanced-stage primary epithelial ovarian, fallopian tube, or peritoneal carcinoma [J].
Abaid, Lisa N. ;
Micha, John P. ;
Rettenmaier, Mark A. ;
Brown, John V. ;
Mendivil, Alberto A. ;
Lopez, Katrina L. ;
Goldstein, Bram H. .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 72 (01) :101-107
12345